Malignant Pleural Mesothelioma: Surgical Management in 285 Patients

Paul H. Schipper, Francis C. Nichols, Kristine M. Thomse, Claude Deschamps, Stephen D. Cassivi, Mark S. Allen, Peter C. Pairolero

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background: Malignant pleural mesothelioma is a rare, aggressive, and deadly malignancy. Despite increasing incidence, no treatment modality is accepted standard of care. This report analyzes our experience with surgical management of mesothelioma. Methods: All patients with surgery for mesothelioma from January 1985 through December 2003 were retrospectively reviewed. Results: There were 285 patients with a median age of 66 years (range, 26 to 91 years). One hundred forty-six patients (51%) had biopsy only, 73 (26%) had extrapleural pneumonectomy, 34 (12%) had subtotal parietal pleurectomy, 22 (8%) underwent exploration without resection, and 10 (3%) had total pleurectomy. Histopathology was epithelial, nonepithelial, and unclassified in 134, 108, and 43 patients, respectively. Twenty patients were stage IA, 82 patients were stage IB, 24 patients were stage II, 75 patients were stage III, 60 patients were stage IV, and 24 patients were of unknown stage. Fifty-three patients (19%) had chemotherapy alone, 16 (5.6%) had radiation alone, and 42 (14.7%) had both. Thirty-day operative mortality was 6.3% and was not significantly associated with the operative procedure (p = 0.79). Fifty-one percent of extrapleural pneumonectomy patients had major complications, significantly greater than patients having any other procedure (p < 0.001). Median follow-up was 11 months (range, 0 to 7 years). Overall median survival was 10.7 months; however, for patients having extrapleural pneumonectomy, median survival was 16 months. One-, 2-, and 3-year survival after extrapleural pneumonectomy was 61%, 25%, and 14%, respectively. Conclusions: Extrapleural pneumonectomy can be performed with similar 30-day mortality as other procedures for malignant pleural mesothelioma with a median survival better than subtotal pleurectomy, exploration without resection, and biopsy alone. However, extrapleural pneumonectomy has significant morbidity and a 3-year survival of only 14%.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalAnnals of Thoracic Surgery
Volume85
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Pneumonectomy
Survival
Mesothelioma
Malignant Mesothelioma
Biopsy
Mortality
Operative Surgical Procedures
Standard of Care
Radiation
Morbidity
Drug Therapy
Incidence
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Schipper, P. H., Nichols, F. C., Thomse, K. M., Deschamps, C., Cassivi, S. D., Allen, M. S., & Pairolero, P. C. (2008). Malignant Pleural Mesothelioma: Surgical Management in 285 Patients. Annals of Thoracic Surgery, 85(1), 257-264. https://doi.org/10.1016/j.athoracsur.2007.06.066

Malignant Pleural Mesothelioma : Surgical Management in 285 Patients. / Schipper, Paul H.; Nichols, Francis C.; Thomse, Kristine M.; Deschamps, Claude; Cassivi, Stephen D.; Allen, Mark S.; Pairolero, Peter C.

In: Annals of Thoracic Surgery, Vol. 85, No. 1, 01.2008, p. 257-264.

Research output: Contribution to journalArticle

Schipper, PH, Nichols, FC, Thomse, KM, Deschamps, C, Cassivi, SD, Allen, MS & Pairolero, PC 2008, 'Malignant Pleural Mesothelioma: Surgical Management in 285 Patients', Annals of Thoracic Surgery, vol. 85, no. 1, pp. 257-264. https://doi.org/10.1016/j.athoracsur.2007.06.066
Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS et al. Malignant Pleural Mesothelioma: Surgical Management in 285 Patients. Annals of Thoracic Surgery. 2008 Jan;85(1):257-264. https://doi.org/10.1016/j.athoracsur.2007.06.066
Schipper, Paul H. ; Nichols, Francis C. ; Thomse, Kristine M. ; Deschamps, Claude ; Cassivi, Stephen D. ; Allen, Mark S. ; Pairolero, Peter C. / Malignant Pleural Mesothelioma : Surgical Management in 285 Patients. In: Annals of Thoracic Surgery. 2008 ; Vol. 85, No. 1. pp. 257-264.
@article{26c3530c4690449cac31986c2841d527,
title = "Malignant Pleural Mesothelioma: Surgical Management in 285 Patients",
abstract = "Background: Malignant pleural mesothelioma is a rare, aggressive, and deadly malignancy. Despite increasing incidence, no treatment modality is accepted standard of care. This report analyzes our experience with surgical management of mesothelioma. Methods: All patients with surgery for mesothelioma from January 1985 through December 2003 were retrospectively reviewed. Results: There were 285 patients with a median age of 66 years (range, 26 to 91 years). One hundred forty-six patients (51{\%}) had biopsy only, 73 (26{\%}) had extrapleural pneumonectomy, 34 (12{\%}) had subtotal parietal pleurectomy, 22 (8{\%}) underwent exploration without resection, and 10 (3{\%}) had total pleurectomy. Histopathology was epithelial, nonepithelial, and unclassified in 134, 108, and 43 patients, respectively. Twenty patients were stage IA, 82 patients were stage IB, 24 patients were stage II, 75 patients were stage III, 60 patients were stage IV, and 24 patients were of unknown stage. Fifty-three patients (19{\%}) had chemotherapy alone, 16 (5.6{\%}) had radiation alone, and 42 (14.7{\%}) had both. Thirty-day operative mortality was 6.3{\%} and was not significantly associated with the operative procedure (p = 0.79). Fifty-one percent of extrapleural pneumonectomy patients had major complications, significantly greater than patients having any other procedure (p < 0.001). Median follow-up was 11 months (range, 0 to 7 years). Overall median survival was 10.7 months; however, for patients having extrapleural pneumonectomy, median survival was 16 months. One-, 2-, and 3-year survival after extrapleural pneumonectomy was 61{\%}, 25{\%}, and 14{\%}, respectively. Conclusions: Extrapleural pneumonectomy can be performed with similar 30-day mortality as other procedures for malignant pleural mesothelioma with a median survival better than subtotal pleurectomy, exploration without resection, and biopsy alone. However, extrapleural pneumonectomy has significant morbidity and a 3-year survival of only 14{\%}.",
author = "Schipper, {Paul H.} and Nichols, {Francis C.} and Thomse, {Kristine M.} and Claude Deschamps and Cassivi, {Stephen D.} and Allen, {Mark S.} and Pairolero, {Peter C.}",
year = "2008",
month = "1",
doi = "10.1016/j.athoracsur.2007.06.066",
language = "English (US)",
volume = "85",
pages = "257--264",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Malignant Pleural Mesothelioma

T2 - Surgical Management in 285 Patients

AU - Schipper, Paul H.

AU - Nichols, Francis C.

AU - Thomse, Kristine M.

AU - Deschamps, Claude

AU - Cassivi, Stephen D.

AU - Allen, Mark S.

AU - Pairolero, Peter C.

PY - 2008/1

Y1 - 2008/1

N2 - Background: Malignant pleural mesothelioma is a rare, aggressive, and deadly malignancy. Despite increasing incidence, no treatment modality is accepted standard of care. This report analyzes our experience with surgical management of mesothelioma. Methods: All patients with surgery for mesothelioma from January 1985 through December 2003 were retrospectively reviewed. Results: There were 285 patients with a median age of 66 years (range, 26 to 91 years). One hundred forty-six patients (51%) had biopsy only, 73 (26%) had extrapleural pneumonectomy, 34 (12%) had subtotal parietal pleurectomy, 22 (8%) underwent exploration without resection, and 10 (3%) had total pleurectomy. Histopathology was epithelial, nonepithelial, and unclassified in 134, 108, and 43 patients, respectively. Twenty patients were stage IA, 82 patients were stage IB, 24 patients were stage II, 75 patients were stage III, 60 patients were stage IV, and 24 patients were of unknown stage. Fifty-three patients (19%) had chemotherapy alone, 16 (5.6%) had radiation alone, and 42 (14.7%) had both. Thirty-day operative mortality was 6.3% and was not significantly associated with the operative procedure (p = 0.79). Fifty-one percent of extrapleural pneumonectomy patients had major complications, significantly greater than patients having any other procedure (p < 0.001). Median follow-up was 11 months (range, 0 to 7 years). Overall median survival was 10.7 months; however, for patients having extrapleural pneumonectomy, median survival was 16 months. One-, 2-, and 3-year survival after extrapleural pneumonectomy was 61%, 25%, and 14%, respectively. Conclusions: Extrapleural pneumonectomy can be performed with similar 30-day mortality as other procedures for malignant pleural mesothelioma with a median survival better than subtotal pleurectomy, exploration without resection, and biopsy alone. However, extrapleural pneumonectomy has significant morbidity and a 3-year survival of only 14%.

AB - Background: Malignant pleural mesothelioma is a rare, aggressive, and deadly malignancy. Despite increasing incidence, no treatment modality is accepted standard of care. This report analyzes our experience with surgical management of mesothelioma. Methods: All patients with surgery for mesothelioma from January 1985 through December 2003 were retrospectively reviewed. Results: There were 285 patients with a median age of 66 years (range, 26 to 91 years). One hundred forty-six patients (51%) had biopsy only, 73 (26%) had extrapleural pneumonectomy, 34 (12%) had subtotal parietal pleurectomy, 22 (8%) underwent exploration without resection, and 10 (3%) had total pleurectomy. Histopathology was epithelial, nonepithelial, and unclassified in 134, 108, and 43 patients, respectively. Twenty patients were stage IA, 82 patients were stage IB, 24 patients were stage II, 75 patients were stage III, 60 patients were stage IV, and 24 patients were of unknown stage. Fifty-three patients (19%) had chemotherapy alone, 16 (5.6%) had radiation alone, and 42 (14.7%) had both. Thirty-day operative mortality was 6.3% and was not significantly associated with the operative procedure (p = 0.79). Fifty-one percent of extrapleural pneumonectomy patients had major complications, significantly greater than patients having any other procedure (p < 0.001). Median follow-up was 11 months (range, 0 to 7 years). Overall median survival was 10.7 months; however, for patients having extrapleural pneumonectomy, median survival was 16 months. One-, 2-, and 3-year survival after extrapleural pneumonectomy was 61%, 25%, and 14%, respectively. Conclusions: Extrapleural pneumonectomy can be performed with similar 30-day mortality as other procedures for malignant pleural mesothelioma with a median survival better than subtotal pleurectomy, exploration without resection, and biopsy alone. However, extrapleural pneumonectomy has significant morbidity and a 3-year survival of only 14%.

UR - http://www.scopus.com/inward/record.url?scp=37249015908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249015908&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2007.06.066

DO - 10.1016/j.athoracsur.2007.06.066

M3 - Article

C2 - 18154820

AN - SCOPUS:37249015908

VL - 85

SP - 257

EP - 264

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -